F1000Prime recommendation of Moving targets in sodium channel blocker development: the case of raxatrigine: from a central NaV1.3 blocker via a peripheral NaV1.7 blocker to a less selective sodium channel blocker.
2019
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI